Jeffcott L B, Colles C M
Equine Vet J. 1977 Jul;9(3):105-10. doi: 10.1111/j.2042-3306.1977.tb03997.x.
The clinical uses and side-effects of phenylbutazone in man, horses, and other animals are reviewed. The blood dyscrasias commonly described in man have not been reported in the horse, although several of the more minor side-effects have occasionally been seen (e.g. water retention, depression, transient staggering and phlebitis). Despite the lack of documented evidence, the toxicity of phenylbutazone in the horse is considered to be lower than that in man. This may be associated with the lower dose rates normally used, the more rapid plasma clearance rate and the comparatively younger age of most horses under treatment. The following guidelines for the use of phenylbutazone in practice are put toward. It should only be used under strict veterinary control and then only if there are clear clinical indications. It should not be given if there are signs of gastro-intestinal ulceration, clotting defects or any cardiac, renal or hepatic dysfunction. Dose rates should be kept to a minimum and the drug withdrawn immediately if any side-effects occur or if there is no clinical response within 4 days. If prolonged therapy is necessary, periodic haematological analyses should be carried out.
本文综述了保泰松在人、马及其他动物中的临床应用和副作用。虽然在马身上偶尔会出现一些较轻微的副作用（如水潴留、抑郁、短暂蹒跚和静脉炎），但人身上常见的血液恶液质在马身上尚未有报道。尽管缺乏文献证据，但保泰松在马身上的毒性被认为低于在人身上的毒性。这可能与通常使用的较低剂量率、更快的血浆清除率以及大多数接受治疗的马相对年轻的年龄有关。以下是在实际应用中使用保泰松的指导原则。它仅应在严格的兽医控制下使用，且只有在有明确的临床指征时才能使用。如果有胃肠道溃疡、凝血缺陷或任何心脏、肾脏或肝脏功能障碍的迹象，则不应给予。剂量率应保持在最低水平，如果出现任何副作用或在4天内没有临床反应，应立即停药。如果需要长期治疗，应定期进行血液学分析。
